Drug Trial Radar · NCT05570058
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Sep 8, 2022
Primary completion
Jun 25, 2024
Study completion Jan 9, 2025
Sponsor
- Lead sponsor
- Redx Pharma LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Simbec-Orion Group
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.
Conditions
- IPF
- Fibrosis
Interventions
RXC007Drug
RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
PlaceboDrug
The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of AEs and SAEs Changes in safety laboratory parameters, vital signs, and ECGsTime frame: From Day 1 to post-study follow up visit (12 weeks)
- Number of participants who report a change from normal range values for laboratory safety parameters (serum biochemistry, serum haematology or urinalysis) from first dose on Day 1 to post-study follow up visit.Time frame: From Day 1 to post-study follow up visit (12 weeks)
- Number of participants who report a change from normal range values for vital signs parameters (blood pressure, pulse rate, respiration rate, oral body temperature) from first dose on Day 1 to 12 weeks of treatmentTime frame: From Day 1 to post-study follow up visit (12 weeks)
- Number of participants who report a change from normal range values for any of the associated 12-Lead ECG parameters (heart rate, QT interval and QTcF interval) from first dose on Day 1 up to completion of the post-study visit.Time frame: From Day 1 to post-study follow up visit (12 weeks)
Locations
31 sites in 8 countries. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, Austria
E PNE UZ Leuven
Leuven, Belgium
CHU De Liège
Liège, Belgium
Pneumologicka klinika 1.LF UK a
Prague, Czechia
Azienda Ospedaliero-Universitaria "Ospedali-Riuniti" di Ancona
Ancona, Italy
Azienda Ospedaliero Universitaria Policlinico ''G.Rodolico-San Marco''
Catania, Italy
Colonello D'avanzo Hospital
Foggia, Italy
PO Vito Fazzi
Lecce, Italy
Ospedale S. Giuseppe Milano
Milan, Italy
Azienda Ospedaliera Universitaria of Modena
Modena, Italy
Fondazione Policlinico Universitario A. Gemelli
Roma, Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy
University Clinical Centre in Gdansk
Gdansk, Poland
Barlicki University Hospital
Lodz, Poland
Institute of Tuberculosis and Lung Diseases in Warsaw
Warsaw, Poland
Policlinica Barcelona
Barcelona, Spain
Hospital Universitario Clínic de Barcelona
Barcelona, Spain
L'Hospital Universitari de Bellvitge
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Central de Asturias
Oviedo, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
University Hospital of Geneve
Geneva, Switzerland
Belfast City Hospital
Belfast, United Kingdom
Queen Elizabeth Hospital
Birmingham, United Kingdom
Royal Papworth Hospital NHSFT
Cambridge, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
Guy's Hospital
London, United Kingdom
Royal Brompton Hospital
London, United Kingdom
Altnagelvin Area Hospital
Londonderry, United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.